Longitudinal analysis of postoperative chemotherapy on oral-gut microbiota in patients with advanced gastric cancer.
[BACKGROUND] Gut microbiota plays a pivotal role in modulating therapeutic responses in malignancies.
APA
Xu S, Li B, et al. (2026). Longitudinal analysis of postoperative chemotherapy on oral-gut microbiota in patients with advanced gastric cancer.. BMC microbiology, 26(1). https://doi.org/10.1186/s12866-025-04704-y
MLA
Xu S, et al.. "Longitudinal analysis of postoperative chemotherapy on oral-gut microbiota in patients with advanced gastric cancer.." BMC microbiology, vol. 26, no. 1, 2026.
PMID
41545931
Abstract
[BACKGROUND] Gut microbiota plays a pivotal role in modulating therapeutic responses in malignancies. Elucidating microbial dynamics during cancer treatment provides critical insights for optimizing therapeutic strategies and prognostic prediction.
[PURPOSE] To investigate longitudinal alterations in oral and gut microbiota during chemotherapy in advanced gastric cancer (GC) patients and their prognostic implications.
[METHODS] This study enrolled 29 advanced GC patients, with tongue coating and fecal samples collected before the 1st (GC0), 2nd (GC1), and 3rd (GC2) chemotherapy cycles, alongside 35 healthy controls. Bacterial communities were profiled via 16 S rRNA V3-V4 sequencing, and fungal communities via 18 S rRNA ITS1-ITS2 sequencing. LEfSe, ROC analysis, Zero-Inflated Beta Regression (ZIBR) modeling, and co-occurrence network analysis were employed to evaluate microbial dynamics and prognostic utility.
[RESULTS] During chemotherapy, oral fungal and gut bacterial richness (ACE and Chao indices) significantly decreased, while gut fungal richness increased. β-diversity analysis revealed minimal structural alterations in oral-gut microbiota. The abundance of intestinal bacterial genus and the fungal (in both intestine and oral cavity) exhibited a decreasing trend, whereas the abundance of intestinal bacterial genera including and significantly increased ( < 0.05) during chemotherapy in patients with advanced GC. In the GC0 group, 23 genera (e.g., oral/gut , oral ) predicted 12-month progression-free survival (PFS) (AUC > 0.7). Longitudinal analysis identified 25 genera (e.g., oral , gut and ) significantly associated with PFS across GC0-GC2 (Joint < 0.05). Co-occurrence networks demonstrated oral bacterial dominance in GC patients, with chemotherapy reducing network complexity.
[CONCLUSION] Continuous chemotherapy exerted significant effects on the oral-gut microbiota co-occurrence networks in advanced GC patients, with pre-chemotherapy microbiota demonstrating prognostic diagnostic value. This study provided microbiological evidence to inform future GC monitoring and personalized therapeutic strategies.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12866-025-04704-y.
[PURPOSE] To investigate longitudinal alterations in oral and gut microbiota during chemotherapy in advanced gastric cancer (GC) patients and their prognostic implications.
[METHODS] This study enrolled 29 advanced GC patients, with tongue coating and fecal samples collected before the 1st (GC0), 2nd (GC1), and 3rd (GC2) chemotherapy cycles, alongside 35 healthy controls. Bacterial communities were profiled via 16 S rRNA V3-V4 sequencing, and fungal communities via 18 S rRNA ITS1-ITS2 sequencing. LEfSe, ROC analysis, Zero-Inflated Beta Regression (ZIBR) modeling, and co-occurrence network analysis were employed to evaluate microbial dynamics and prognostic utility.
[RESULTS] During chemotherapy, oral fungal and gut bacterial richness (ACE and Chao indices) significantly decreased, while gut fungal richness increased. β-diversity analysis revealed minimal structural alterations in oral-gut microbiota. The abundance of intestinal bacterial genus and the fungal (in both intestine and oral cavity) exhibited a decreasing trend, whereas the abundance of intestinal bacterial genera including and significantly increased ( < 0.05) during chemotherapy in patients with advanced GC. In the GC0 group, 23 genera (e.g., oral/gut , oral ) predicted 12-month progression-free survival (PFS) (AUC > 0.7). Longitudinal analysis identified 25 genera (e.g., oral , gut and ) significantly associated with PFS across GC0-GC2 (Joint < 0.05). Co-occurrence networks demonstrated oral bacterial dominance in GC patients, with chemotherapy reducing network complexity.
[CONCLUSION] Continuous chemotherapy exerted significant effects on the oral-gut microbiota co-occurrence networks in advanced GC patients, with pre-chemotherapy microbiota demonstrating prognostic diagnostic value. This study provided microbiological evidence to inform future GC monitoring and personalized therapeutic strategies.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12866-025-04704-y.
같은 제1저자의 인용 많은 논문 (5)
- Schlafen 11 as a predictive biomarker and therapeutic target in cancer: From mechanisms to clinical application.
- Macrophage-Derived Transcriptional Signatures Predict Prognosis and Drug Sensitivity in Thyroid Cancer: Integrative Analysis and Experimental Validation of SMYD3.
- Systematic Identification and Characterization of Causal Risk Genes Implicated in Colorectal Cancer by Integrating GWAS, eQTL, and mQTL Data.
- Efficacy of combined laparoscopic hepatectomy and splenic artery ligation for hepatocellular carcinoma with portal hypertension.
- A simplified multitarget stool test for colorectal cancer and advanced precancerous lesion detection.